Efficacy and safety of camrelizumab plus famitinib in patients with previously treated non-small-cell lung cancer: a single-arm, phase II trial

Efficacy and safety of camrelizumab plus famitinib in patients with previously treated non-small-cell lung cancer: a single-arm, phase II trial

Background: For non-small-cell lung cancer (NSCLC) patients who progressed after first-line chemotherapy, immunotherapy targeting programmed cell death (ligand) 1 has shown promising activity. However, the activity is relatively limited in patients harboring epidermal growth factor receptor (EGFR) m...

書目詳細資料
Main Authors:	Ming Gao, Xia Zhang, Huan Yan, Yan Zhao, Fang Yuan, Decong Sun, Xuejiao Yang, Yanfang Ju, Lijie Wang, Haitao Tao, Luyuan Tian, Changhong Zhao, Junxun Ma, Yi Hu, Zhefeng Liu
格式:	Article
語言:	English
出版:	SAGE Publishing 2025-01-01
叢編:	Therapeutic Advances in Medical Oncology
在線閱讀:	https://doi.org/10.1177/17588359241311058

相似書籍

A multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic cervical squamous cell carcinoma
由: Lingfang Xia, et al.
出版: (2022-12-01)

Camrelizumab plus apatinib for previously treated advanced adrenocortical carcinoma: a single-arm phase 2 trial
由: Yu-Chun Zhu, et al.
出版: (2024-11-01)

Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-1 blockade: data from a multicohort phase 2 studyResearch in context
由: Xi Ding, et al.
出版: (2023-07-01)

Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study
由: Quanren Wang, et al.
出版: (2022-05-01)

Neoadjuvant famitinib and camrelizumab, a new combined therapy allowing surgical resection of the primary site for anaplastic thyroid carcinoma
由: Shuwen Yang, et al.
出版: (2023-01-01)

Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study
由: Qi Zhou, et al.
出版: (2022-01-01)

Study protocol: A single‐arm, multicenter, phase II trial of camrelizumab plus apatinib for advanced nonsquamous NSCLC previously treated with first‐line immunotherapy
由: Puyuan Xing, et al.
出版: (2021-10-01)

First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial
由: Ying Liu, et al.
出版: (2024-02-01)

The Efficacy and Safety of Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer: A Prospective Clinical Study
由: Dongxu Wang, et al.
出版: (2021-04-01)

Single-arm study of camrelizumab plus apatinib for patients with advanced mucosal melanoma
由: Lin Li, et al.
出版: (2024-06-01)

Three-arm phase II trial comparing camrelizumab plus chemotherapy versus camrelizumab plus chemoradiation versus chemoradiation as preoperative treatment for locally advanced esophageal squamous cell carcinoma (NICE-2 Study)
由: Yang Yang, et al.
出版: (2022-05-01)

Case Report: Low-Dose Decitabine Plus Anti-PD-1 Inhibitor Camrelizumab for Previously Treated Advanced Metastatic Non-Small Cell Lung Cancer
由: Xin Yan, et al.
出版: (2020-10-01)

Famitinib enhances the antitumor effect of radioimmunotherapy in murine lung cancer
由: Meng Yuan, et al.
出版: (2022-12-01)

Clinical and biomarker analyses of SHR-1701 combined with famitinib in patients with previously treated advanced biliary tract cancer or pancreatic ductal adenocarcinoma: a phase II trial
由: Lixia Yi, et al.
出版: (2024-12-01)

Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Camrelizumab Compared With Conventional Transarterial Chemoembolization Plus Camrelizumab for Unresectable Hepatocellular Carcinoma
由: Yanqiao Ren, et al.
出版: (2022-03-01)

Transarterial Chemoembolization Plus Camrelizumab and Rivoceranib versus Camrelizumab and Rivoceranib Alone for BCLC Stage C Hepatocellular Carcinoma
由: Zhou WJ, et al.
出版: (2024-12-01)

Neoadjuvant camrelizumab plus nab-paclitaxel and epirubicin in early triple-negative breast cancer: a single-arm phase II trial
由: Chengzheng Wang, et al.
出版: (2023-10-01)

Camrelizumab plus platinum-irinotecan followed by maintenance camrelizumab plus apatinib in untreated extensive-stage small-cell lung cancer: a nonrandomized clinical trial
由: Jun Ni, et al.
出版: (2023-04-01)

Relationship Between Peripheral Blood T Lymphocyte Subsets and Prognosis of Patients with Advanced Non-small Cell Lung Cancer Treated with Camrelizumab
由: DONG Changhong, et al.
出版: (2024-03-01)

Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial
由: Jian Wang, et al.
出版: (2020-10-01)

Cost-effectiveness of camrelizumab plus rivoceranib for advanced hepatocellular carcinoma in the context of regional disparities in China
由: Zhonghua Zhao, et al.
出版: (2024-12-01)

Immuno-genomic-radiomics to predict response of biliary tract cancer to camrelizumab plus GEMOX in a single-arm phase II trial
由: Qiu-Ping Liu, et al.
出版: (2023-07-01)

Multicenter, single-arm, phase II study (CAP) of radiotherapy plus liposomal irinotecan followed by camrelizumab and anti-angiogenic treatment in advanced solid tumors
由: Jie Shen, et al.
出版: (2023-03-01)

Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study
由: Peng Yang, et al.
出版: (2021-11-01)

Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Nonsquamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial
由: Shengxiang Ren, MD, et al.
出版: (2022-05-01)

Transarterial chemoembolization with molecular targeted therapies plus camrelizumab for recurrent hepatocellular carcinoma
由: Changlong Hou, et al.
出版: (2024-03-01)

Transcatheter arterial chemoembolisation combined with lenvatinib plus camrelizumab as conversion therapy for unresectable hepatocellular carcinoma: a single-arm, multicentre, prospective studyResearch in context
由: Xu-Kun Wu, et al.
出版: (2024-01-01)

Cost-effectiveness analysis of camrelizumab plus chemotherapy as first-line treatment for advanced squamous NSCLC in China
由: Taihang Shao, et al.
出版: (2022-08-01)

Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial
由: Ke Wang, et al.
出版: (2022-04-01)

Anlotinib plus camrelizumab achieved long‐term survival in a patient with metastatic esophageal neuroendocrine carcinoma
由: Lingxiao Zhou, et al.
出版: (2023-09-01)

Neoadjuvant therapy with camrelizumab plus gemcitabine and cisplatin for patients with muscle‐invasive bladder cancer: A multi‐center, single‐arm, phase 2 study
由: Sujun Han, et al.
出版: (2023-06-01)

Clinical efficacy and safety evaluation of camrelizumab plus lenvatinib in adjuvant therapy after hepatocellular carcinoma surgery
由: Xudan Wang, et al.
出版: (2023-12-01)

Camrelizumab plus gemcitabine and oxaliplatin for relapsed or refractory classical Hodgkin lymphoma: a phase II trial
由: Yanfei Liu, et al.
出版: (2024-03-01)

Neoadjuvant camrelizumab plus chemotherapy for locally advanced cervical cancer (NACI Study): a study protocol of a prospective, single-arm, phase II trial
由: Jing Chen, et al.
出版: (2023-05-01)

Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation Study
由: Qiuyan Chen, et al.
出版: (2018-11-01)

Immune repertoire sequencing reveals differences in treatment response to camrelizumab plus platinum-based chemotherapy in advanced ESCC
由: Xiaoling Zhang, et al.
出版: (2025-02-01)

Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial
由: Xin Sun, et al.
出版: (2020-05-01)

Apatinib Plus Camrelizumab With/Without Chemoembolization for Hepatocellular Carcinoma: A Real-World Experience of a Single Center
由: Shuguang Ju, et al.
出版: (2022-01-01)

Microwave ablation plus camrelizumab monotherapy or combination therapy in non-small cell lung cancer
由: Yahan Huang, et al.
出版: (2022-08-01)

Camrelizumab Plus Sorafenib Versus Sorafenib Monotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Analysis
由: Qinqin Liu, et al.
出版: (2021-10-01)